Solid-Tubulocystic carcinoma: A new variant of intrahepatic cholangiocarcinoma

Table 1 Aggregated selected immunophenotype[5,6,7,8,11], n (%)

Antibody	Positive	Negative
Inhibin	14 (100)	0
Cytokeratin AE1/AE3	6 (100)	0
CAM5.2	4 (100)	0
Cytokeratin-7	14 (100)	0
Cytokeratin-19	12 (100)	0
Cytokeratin-20	0	6 (100)
CDX2	0	3 (100)
Arginase-1	0	5 (100)
HepPar1	0	13 (100)
Glypican-3	1 (12.5)	7 (87.5)
Glutamine synthetase	3 (100)	0
Albumin by in situ hybridization	6 (100)	0
Synaptophysin	10 (76.9)	3 (23.1)
Chromogranin	9 (64.3)	5 (35.7)
CD56	5 (71.4)	2 (28.6)
INSM1	4 (100)	0
Beta-catenin	0	7 (100)
CD10	0	3 (100)
Pax8	0	2 (100)
Gata3	0	1 (100)
Mammaglobin	0	1 (100)
GCDFP-15	0	1 (100)
ER	0	2 (100)
PR	0	2 (100)
S100	0	3 (100)

CDX2: Caudal-related homeobox gene 2; INSM1: Insulinoma associated protein 1; GCDFP-15: Gross cystic disease fluid protein 15; ER: Estrogen receptor; PR: Progesterone receptor; HMB45: Human melanoma black 45; pCEA: Polyclonal carcinoembryonic antigen; mCEA: Monoclonal carcinoembryonic antigen; SF-1: Steroidogenic factor 1; WT-1: Wilms tumor 1; TTF-1: Thyroid transcription factor 1; AFP: Alpha fetoprotein; CA125: Cancer antigen 125; CA19.9: Cancer antigen 19.9; SALL4: Sal-like 4; Oct3/4: Octamer binding transcription factor 3/4; PLAP: Placental-like alkaline phosphatase; hCG: Human chorionic gonadotrophin; RCC: Renal cell carcinoma; SOX9: SRY-box transcription factor 9.